Taysha announces exclusive option from utsw to license worldwide rights to clinical-stage aav9 gene therapy program for cln7 disease, a research collaboration with utsw to develop next-generation construct for cln7 and a grant award to batten hope

Dallas--(business wire)--taysha gene therapies, inc. (nasdaq: tsha), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns) in both rare and large patient populations, today announced that it has obtained an exclusive option from ut southwestern (utsw) to license worldwide rights to a clinical-stage aav9 gene therapy replacement program for the treatment
TSHA Ratings Summary
TSHA Quant Ranking